FeesSafety
Pluang+

FinChain and Plume launch FLEX & FINO, a leveraged yield strategy targeting 7.2% APY with FUSD collateral.

Protocol Fundamentals
04 Nov 2026, 17:12 WIB
TheNewsCrypto
View Source
Bullish
FinChain and Plume launch FLEX & FINO, a leveraged yield strategy targeting 7.2% APY with FUSD collateral.

FinChain and Plume have introduced FLEX & FINO, a leveraged yield strategy that aims for up to 7.2% annualized returns by using FUSD as collateral and borrowing USDC to invest in DeFi liquidity pools. The strategy combines yields from tokenized U.S. Treasury-backed assets with additional DeFi income through a leveraged looping model. It includes risk controls like a 90% utilization cap, T+2 redemption cycles, and interest settlements between T+14 and T+30. This product marks the first collaboration under their partnership and highlights FinChain's integration with KuCoin for further DeFi participation.

FinChain and Plume's new leveraged RWA yield strategy is the subject, with Pluang market data providing context as of Nov 04, 2026 21:23 WIB. Among 50 major cryptocurrencies priced on Pluang, 30 rose and 19 fell today. Notable movers include XNO at Rp5.954 with a 3.15% increase and a Pluang order activity skewed 96% Sell / 4% Buy, CRV at Rp4.904 up 3.13% with 63% Sell / 37% Buy, and GRT at Rp365 rising 2.68% with 93% Sell / 7% Buy. The most notable figure is XNO's 96% sell order activity.

More News

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...

Market News
Bearish
25 minutes ago
Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...

Company Fundamentals
Bullish
25 minutes ago
ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...

Market News
Bullish
25 minutes ago
New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...

Others
Bullish
25 minutes ago
Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...

Market News
Bullish
25 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App